Get Ready for the Virtual TTS 2024 Program Starting Monday!

We are excited to announce that the virtual portion of TTS 2024 kicks off this Monday! We can’t wait to welcome everyone to what promises to be an engaging and insightful event. We’ve updated the program to ensure the best experience for our virtual attendees, and we encourage you to explore the exciting sessions and speakers lined up.

TTS 2024 Attendees Access

The Congress Webapp (app.tts2024.org) combines both the live and virtual agendas as well as congress recordings, click the button below for the full program. TTS 2024 delegates may login with the same email and password used at the Congress.

View full program in the WebApp - app.tts2024.org

TTS 2024 Virtual Registration for Non-Members

Includes recordings from September 22-25 and upcoming live virtual sessions from October 21-23!

Click for details

TTS Member Access

TTS Members may view the October 21-23 live virtual sessions for no fee. Members may login into their member account on tts.org to gain access to the sessions. Once logged in click on the "TTS 2024 Oct 21-23 Member Virtual" link under the "Member Area" menu.

Click here to access the program preview on tts.org website

Transplantation Journal Highlights

Transplantation - Social Media Content

The Promise of Complement Therapeutics in Solid Organ Transplantation

Transplantation is the ideal therapy for end-stage organ failure, but outcomes for all transplant organs are suboptimal, underscoring the need to develop novel approaches to improve graft survival and function. The complement system, traditionally considered a component of innate immunity, is now known to broadly control inflammation and crucially contribute to induction and function of adaptive T-cell and B-cell immune responses, including those induced by alloantigens.

Transplantation Direct - Social Media Content

Submit Your Basic Science Research to Transplantation Direct

Inspire the transplantation community by publishing your best research in Transplantation Direct

Why publish in Transplantation Direct?

Global reach
Comprehensive coverage
Expert review within 21 days
Strong social media promotion
Open Access

We look forward to receiving your manuscripts!

Click here to submit today!

Impact of Dialysis Time on Long-term Outcomes in HLA-identical Living Donor Kidney Transplant Recipients

Dialysis vintage is associated with worse outcomes after kidney transplantation. The reasons behind this observation include immunological and nonimmunological risk factors. To mitigate the influence of immunological factors, we examined the association between time on dialysis and clinical outcomes in a cohort of HLA-identical kidney transplant recipients.

5^th Summit on Stem Cell Derived Islets - Online Registration Closes October 22nd!

Join 200 delegates and speakers representing leading experts and key opinion leaders in the field!

The International Pancreas and Islet Transplant Association (IPITA), the Harvard Stem Cell Institute (HSCI), and Breakthrough T1D (formerly JDRF) are hosting the 5th Summit on Stem Cell-Derived Islets at the Joseph B. Martin Conference Center in Boston, MA, USA, from October 28-29, 2024. This Summit will highlight the latest breakthroughs in stem cell-derived islet biology and complementary technologies, alongside showcasing the progress of clinical trials in this cutting-edge field. The program will feature presentations from world-renowned experts, offering insights into groundbreaking science and state-of-the-art advancements.

Visit the website

Click here to View the Detailed Program

Monday, October 28, 2024

07:00

Registration opens

08:00-08:15

Welcome and Introductory Comments

Welcome from: Jon Odorico and James Markmann

08:15-09:30

Session 1
Insights from Islet Biology for Making Stem Cell-Derived Islets

Moderator: Albert Hwa

08:15-08:30

Insights into islet biology from the human pancreas and beyond

Alvin Powers, Vanderbilt University, United States
08:30-08:45

Insights into beta cell development from stem cells

Matthias Hebrok, Technical University of Munich, Germany
08:45-09:00

Using stem cell islets to gain insights into human pancreas development

Danwei Huangfu, Memorial Sloan Kettering, United States
09:00-09:15

Using human pancreas slices to understand islet physiology and function

Joana Collares Pereira Almaca, University of Miami School of Medicine, United States
09:15-09:30

Panel Discussion

09:30-10:00

Coffee Break

10:00-11:15

Session 2
Optimizing Differentiation to Stem Cell Beta Cells

Moderator: Cristina Nostro

10:00-10:15

Tuning developmental signaling during stem cell-derived islet differentiation

Nathaniel Hogrebe, Washington University School of Medicine, United States
10:15-10:30

Functional maturation of stem cell islets

Diego Balboa, University of Helsinki, Finland
10:30-10:45

Origin and development of off-target cell populations arising during stem cell to islet differentiation

Christian Honoré, Cell Therapy R&D, Novo Nordisk A/S, Denmark
10:45-11:00

Scalable generation of 3D stem cell islet organoids or Hallmarks and triggers of beta cell maturation

Juan Alvarez-Dominguez, University of Pennsylvania, United States
11:00-11:15

Panel Discussion

11:15-11:30

Stretch Break

11:30-12:45

Session 3
Immunology of T1D

Moderator: Lorenzo Piemonti

11:30-11:45

Type 1 diabetes as a disease of the beta-cell

Bart Roep, Leiden University Medical Center, Netherlands
11:45-12:00

Neoantigens and autoimmunity triggering mechanisms

Eddie James, Benroya Research Institute, United States
12:00-12:15

Tracking antigen-specific T cell receptors during T1D progression

Maki Nakayama, University of Colorado, United States
12:15-12:30

Modeling the immune infiltration of human stem cell-derived islets in vivo

Remi Creusot, Columbia University, United States
12:30-12:45

Panel Discussion

12:45-13:45

Lunch Break, Poster Viewing & Group Photo

13:45-14:15

Keynote Address

Introduction: Doug Melton

13:45-14:15

Disease Modifying Therapies and rationale for combining with stem cell islets

Tom Kay, St Vincent's Hospital, Australia

14:15-15:15

Session 4A
Best Abstracts Session I

Moderator: Antonio Citro

Abstract 1

Anja Ivis

Strategies for preventing the formation of cytotoxic IAPP amyloid in human stem cell-derived islets
Abstract 2

Hong Qian

Development of a biovascular pancreas to deliver stem cell-derived islets as a therapy for type 1 diabetes
Abstract 3

Anup Nair

Modeling the effects of early hyperinsulinemia due to the R1420H SUR1 mutation using isogenic iPSC derived pancreatic Islets
Abstract 4

Sophia Kioulaphides

Human stem cell-derived beta-cells delivered with vasculogenic hydrogels reverse hyperglycemia in diabetic immunodeficient mice
Abstract 5

Veronica Cochrane

SC-beta cell MafA expression: for better or worse
Abstract 6

Paraish Misra

Islet versus enterochromaffin lineage allocation of hPSC-derived pancreatic progenitors can be modulated at both pre-progenitor and post-progenitor stages

15:15-15:45

Coffee Break

15:45-16:45

Session 4B
Best Abstracts Session II

Moderator: Tom Kay

Abstract 1

Pere Catala

Ultrafast Volumetric Bioprinting of an Endocrine Pancreas Using Functional Human iPSC-Derived Islets
Abstract 2

Francesco Campo

Bio-fabrication of a Human iPSC-based vascularized endocrine pancreas for the treatment of Type 1 Diabetes
Abstract 3

Saleth Dharmaraj

A perfusable encapsulation device housing Stem cell derived pseudo-islets to treat type-1 diabetes
Abstract 4

Ji Lei

Identifying optimal engraftment sites for human stem cell-derived islets in a non-Human primate model
Abstract 5

Nicole Wojcik

Optimization of immunosuppression for beta cell replacement therapy: assessing the tolerability and efficacy of belatacept combined with reduced tacrolimus
Abstract 6

Daniel Tremmel

Islet vascularized ECM organoid (IVEO) constructs repair isolated islets native environment for successful engraftment and functionality post-transplantation

16:45-18:00

Session 5
Immune Evasive Islets

Moderator: Holger Russ

16:45-17:00

PIDO induced islet immune protection from allo and xeno immunity

Jacques Galipeau, University of Wisconsin School of Medicine and Public Health, United States
17:00-17:15

Hypoimmune Stem Cell Islets

Sonja Schrepfer, Sana Biotechnology, United States
17:15-17:30

Genome editing of stem cell islets for hypoimmunity

Audrey Parent, University of California San Francisco Diabetes Center, United States
17:30-17:45

Combinatorial genome engineering strategy for antigen specific protection of stem cell derived beta cells by CAR Tregs

Jessie Barra, University of Florida College of Medicine, United States
17:45-18:00

Panel Discussion

18:00-18:05

Day One Wrap Up

18:05-19:30

Networking Reception

Tuesday, October 29, 2024

07:00

Registration opens

07:30-08:45

Session 6
Beta Cell Replacement Clinical Trials Update

Moderator: Jon Odorico

07:30-07:50

Vertex Trials Update

Michael Rickels, University of Pennsylvania, United States
07:50-08:10

CD40L immunosuppression and Sernova Islet transplant trials

Piotr Witkowski, Transplant Institute University of Chicago Medicine, United States
08:10-08:30

Parathyroid gland supplemented human islet engraftment and function in humans

Peter Stock, University of California San Francisco, United States
08:30-08:45

Panel Discussion

08:45-09:00

Stretch Break

09:00-10:15

Session 7
Immunomodulation/Encapsulation

Moderator: James Markmann

09:00-09:15

Overview of Immunomodulation Strategies

Alessandro Grattoni, Houston Methodist Hospital, United States
09:15-09:30

Role of EVs in Immunomodulation of stem cell islets

Edward Phelps, University of Florida, United States
09:30-09:45

CD40L immunotherapy to protect transplanted islets

Norma Kenyon, University of Miami Miller School of Medicine, United States
09:45-10:00

The Good and Bad of Humanized Mouse Models

Michael Brehm, University of Massachusetts Chan Medical School, United States
10:00-10:15

Panel Discussion

10:15-10:45

Coffee Break

10:45-12:00

Session 8
Overcoming challenges to broader clinical application of stem cell-derived islets

Moderator: Esther Latres

10:45-11:00

Successful cryopreservation of intact stem cell islets

Joseph Sushil Rao, University of Minnesota, United States
11:00-11:15

Delivering insulin-producing cells without immunosuppression

Minglin Ma, Cornell University, United States
11:15-11:30

Novel scale up technologies

Kevin Alessandri, TreeFrog Therapeutics, United States
11:30-12:00

Panel Discussion

12:00-13:00

Lunch Break & Poster Viewing

13:00-13:30

Session 9
Best Abstracts Session III

Moderator: Michael Rickels

Abstract 1

Sonja Schrepfer

Hypoimmune Islet Cells Mediate Insulin Independence After Allogeneic Transplantation Without Immunosuppression
Abstract 2

Kfir Molakandov

IsletRxPlus, CD26− and CD49A+ enriched hESC-derived Islet cells, improves safety and identity profile in diabetic mice at multiple implantation sites.
Abstract 3

Caterra Leavens

The beta cell “invisibility cloak” – Developing stem cell-derived pancreatic islets that are protected from the immune system
Abstract 4

Mina Seedhom

Study of interactions between human immune systems and SC-islets from T1D individuals in a novel NSG MHC-DKO Tg(hIL15) mouse

13:30-15:05

Session 10
Future Opportunities And Barriers for Broad Clinical Application

13:30-14:15

Panel 1
Manufacturing, Scale Up, Regulatory
Moderator: Jeffrey Millman

Felicia Pagliuca, Vertex Pharmaceuticals, Inc. United States
Heather Lombardi, FDA - CBER, United States
Tom Bollenbach, BiofabUSA, United States
14:20-15:05

Panel 2
Eligibility Criteria and Future Clinical Trial Design
Moderator: Eelco DeKoning

Lorenzo Piemonti, Universita Vita-Salute San Raffaele, Italy
Trevor Reichman, U Toronto, Canada
Marjana Marinac, Breakthrough T1D, United States